Cargando…

A Requirement for Argonaute 4 in Mammalian Antiviral Defense

While interferon (IFN) responses are critical for mammalian antiviral defense, induction of antiviral RNA interference (RNAi) is evident. To date, individual functions of the mammalian RNAi and micro RNA (miRNA) effector proteins Argonautes 1–4 (AGO1–AGO4) during virus infection remain undetermined....

Descripción completa

Detalles Bibliográficos
Autores principales: Adiliaghdam, Fatemeh, Basavappa, Megha, Saunders, Tahnee L., Harjanto, Dewi, Prior, John T., Cronkite, D. Alexander, Papavasiliou, Nina, Jeffrey, Kate L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039342/
https://www.ncbi.nlm.nih.gov/pubmed/32049003
http://dx.doi.org/10.1016/j.celrep.2020.01.021
_version_ 1783500797622878208
author Adiliaghdam, Fatemeh
Basavappa, Megha
Saunders, Tahnee L.
Harjanto, Dewi
Prior, John T.
Cronkite, D. Alexander
Papavasiliou, Nina
Jeffrey, Kate L.
author_facet Adiliaghdam, Fatemeh
Basavappa, Megha
Saunders, Tahnee L.
Harjanto, Dewi
Prior, John T.
Cronkite, D. Alexander
Papavasiliou, Nina
Jeffrey, Kate L.
author_sort Adiliaghdam, Fatemeh
collection PubMed
description While interferon (IFN) responses are critical for mammalian antiviral defense, induction of antiviral RNA interference (RNAi) is evident. To date, individual functions of the mammalian RNAi and micro RNA (miRNA) effector proteins Argonautes 1–4 (AGO1–AGO4) during virus infection remain undetermined. AGO2 was recently implicated in mammalian antiviral defense, so we examined antiviral activity of AGO1, AGO3, or AGO4 in IFN-competent immune cells. Only AGO4-deficient cells are hyper-susceptible to virus infection. AGO4 antiviral function is both IFN dependent and IFN independent, since AGO4 promotes IFN but also maintains antiviral capacity following prevention of IFN signaling or production. We identified AGO-loaded virus-derived short interfering RNAs (vsiRNAs), a molecular marker of antiviral RNAi, in macrophages infected with influenza or influenza lacking the IFN and RNAi suppressor NS1, which are uniquely diminished without AGO4. Importantly, AGO4-deficient influenza-infected mice have significantly higher burden and viral titers in vivo. Together, our data assign an essential role for AGO4 in mammalian antiviral defense.
format Online
Article
Text
id pubmed-7039342
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-70393422020-02-24 A Requirement for Argonaute 4 in Mammalian Antiviral Defense Adiliaghdam, Fatemeh Basavappa, Megha Saunders, Tahnee L. Harjanto, Dewi Prior, John T. Cronkite, D. Alexander Papavasiliou, Nina Jeffrey, Kate L. Cell Rep Article While interferon (IFN) responses are critical for mammalian antiviral defense, induction of antiviral RNA interference (RNAi) is evident. To date, individual functions of the mammalian RNAi and micro RNA (miRNA) effector proteins Argonautes 1–4 (AGO1–AGO4) during virus infection remain undetermined. AGO2 was recently implicated in mammalian antiviral defense, so we examined antiviral activity of AGO1, AGO3, or AGO4 in IFN-competent immune cells. Only AGO4-deficient cells are hyper-susceptible to virus infection. AGO4 antiviral function is both IFN dependent and IFN independent, since AGO4 promotes IFN but also maintains antiviral capacity following prevention of IFN signaling or production. We identified AGO-loaded virus-derived short interfering RNAs (vsiRNAs), a molecular marker of antiviral RNAi, in macrophages infected with influenza or influenza lacking the IFN and RNAi suppressor NS1, which are uniquely diminished without AGO4. Importantly, AGO4-deficient influenza-infected mice have significantly higher burden and viral titers in vivo. Together, our data assign an essential role for AGO4 in mammalian antiviral defense. 2020-02-11 /pmc/articles/PMC7039342/ /pubmed/32049003 http://dx.doi.org/10.1016/j.celrep.2020.01.021 Text en This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Adiliaghdam, Fatemeh
Basavappa, Megha
Saunders, Tahnee L.
Harjanto, Dewi
Prior, John T.
Cronkite, D. Alexander
Papavasiliou, Nina
Jeffrey, Kate L.
A Requirement for Argonaute 4 in Mammalian Antiviral Defense
title A Requirement for Argonaute 4 in Mammalian Antiviral Defense
title_full A Requirement for Argonaute 4 in Mammalian Antiviral Defense
title_fullStr A Requirement for Argonaute 4 in Mammalian Antiviral Defense
title_full_unstemmed A Requirement for Argonaute 4 in Mammalian Antiviral Defense
title_short A Requirement for Argonaute 4 in Mammalian Antiviral Defense
title_sort requirement for argonaute 4 in mammalian antiviral defense
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039342/
https://www.ncbi.nlm.nih.gov/pubmed/32049003
http://dx.doi.org/10.1016/j.celrep.2020.01.021
work_keys_str_mv AT adiliaghdamfatemeh arequirementforargonaute4inmammalianantiviraldefense
AT basavappamegha arequirementforargonaute4inmammalianantiviraldefense
AT saunderstahneel arequirementforargonaute4inmammalianantiviraldefense
AT harjantodewi arequirementforargonaute4inmammalianantiviraldefense
AT priorjohnt arequirementforargonaute4inmammalianantiviraldefense
AT cronkitedalexander arequirementforargonaute4inmammalianantiviraldefense
AT papavasiliounina arequirementforargonaute4inmammalianantiviraldefense
AT jeffreykatel arequirementforargonaute4inmammalianantiviraldefense
AT adiliaghdamfatemeh requirementforargonaute4inmammalianantiviraldefense
AT basavappamegha requirementforargonaute4inmammalianantiviraldefense
AT saunderstahneel requirementforargonaute4inmammalianantiviraldefense
AT harjantodewi requirementforargonaute4inmammalianantiviraldefense
AT priorjohnt requirementforargonaute4inmammalianantiviraldefense
AT cronkitedalexander requirementforargonaute4inmammalianantiviraldefense
AT papavasiliounina requirementforargonaute4inmammalianantiviraldefense
AT jeffreykatel requirementforargonaute4inmammalianantiviraldefense